Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Principal TechnologiesFRA:JO7 +0.25%14 ROC (Joel Greenblatt) % is -34,953.85% as of Apr. 2026. GuruFocus rates FRA:JO7 with a GF Score™ of 14/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Principal Technologies ranks worse than 97.01% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Principal Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -34,953.85%.
The historical rank and industry rank for Principal Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:JO7'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11161.97 Med: -1590.44 Max: -1207.19
Current: -11161.97
During the past 6 years, Principal Technologies's highest ROC (Joel Greenblatt) % was -1207.19%. The lowest was -11161.97%. And the median was -1590.44%.
FRA:JO7's ROC (Joel Greenblatt) % is ranked worse than 97.01% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 12.46
vs FRA:JO7: -11161.97
Principal Technologies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Principal Technologies (FRA:JO7) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Principal Technologies ROC (Joel Greenblatt) % Related Terms
Principal Technologies ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Principal Technologies's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Principal Technologies ROC (Joel Greenblatt) % Chart
FRA:JO7 vs VEEV, BTSG, TEM: ROC (Joel Greenblatt) % Comparison
For the Health Information Services subindustry, Principal Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Principal Technologies ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Principal Technologies's ROC (Joel Greenblatt) % falls into.
Principal Technologies ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -34,953.85% mean?
Principal Technologies (FRA:JO7) has a ROC (Joel Greenblatt) % of -34,953.85% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Principal Technologies and its competitors. According to the industry distribution chart, Principal Technologies ranks #649 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 97%.
Is Principal Technologies' ROC (Joel Greenblatt) % too high?
Principal Technologies' current ROC (Joel Greenblatt) % is -34,953.85%. Based on the distribution chart, Principal Technologies ranks #649 out of 669 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Principal Technologies has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Principal Technologies' ROC (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Principal Technologies ranks #649 out of 669 companies for ROC (Joel Greenblatt) %. This places Principal Technologies in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.46, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Principal Technologies and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Principal Technologies's current ROC (Joel Greenblatt) % is -34,953.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Principal Technologies stock overvalued right now?
Based on GuruFocus' analysis, Principal Technologies (FRA:JO7) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.20 — trading 395% above its estimated fair value. The current ROC (Joel Greenblatt) % is -34,953.85%. Principal Technologies' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Principal Technologies (FRA:JO7), the current ROC (Joel Greenblatt) % is -34,953.85% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Principal Technologies (FRA:JO7) Overvalued in 2026?
Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued.
The current stock price of €0.20 is trading 395% above its estimated GF Value™ of €0.04.
GuruFocus considers Principal Technologies to be Significantly Overvalued.
Key valuation signals for FRA:JO7:
ROC (Joel Greenblatt) %: -34,953.85%
GF Value™: €0.04 vs. price of €0.20 (395% above fair value)
No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
14GF Score
Get the complete analysis for FRA:JO7
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JO7 has been successfully added to your 
